Streetwise Reports
The Gold Report
The Energy Report
The Life Sciences Report
Research Reports
Streetwise Reports
The Gold Report
The Energy Report
The Life Sciences Report
Research Reports
The Life Sciences Report
Menu
Articles
Biotechnology / Pharmaceuticals
Cannabis
Healthcare Services
Life Sciences Tools & Diagnostics
Medical Devices
Nutraceuticals
Psychedelics
Disclosures
Featured news in
The Life Sciences Report
Mesoblast Ltd.
(MESO:NASDAQ; MSB:ASX)
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up (3/27/2024)
view
MiMedx Group Inc.
(MDXG:NASDAQ)
MIMEDX Provides Update on AXIOFILL® Request for Designation ("RFD") from FDA (3/27/2024)
view
Mesoblast Ltd.
(MESO:NASDAQ; MSB:ASX)
Notable 26 March 2024 Newsmakers (3/26/2024)
view
Mesoblast Ltd.
(MESO:NASDAQ; MSB:ASX)
US Companies Moving the Markets, Evening edition
Tue, Mar 26, 2024 as of 4:00 pm ET (3/26/2024)
view
Mesoblast Ltd.
(MESO:NASDAQ; MSB:ASX)
US Companies Moving the Markets, Morning edition
Tue, Mar 26, 2024 as of 10.00 am ET (3/26/2024)
view
Mesoblast Ltd.
(MESO:NASDAQ; MSB:ASX)
Mesoblast Ltd. (NASDAQ: MESO) is One of Tuesday Morning's Most Active Stocks (3/26/2024)
view
Mesoblast Ltd.
(MESO:NASDAQ; MSB:ASX)
FDA Commentary Sends Biotech Soaring During Premarket Hours (3/26/2024)
view
Mesoblast Ltd.
(MESO:NASDAQ; MSB:ASX)
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) (3/25/2024)
view